Orgenesis signs JV with Korean CGT developer
“The joint venture and partnership with Orgenesis will provide a significant international route to market for our immunotherapies targeting cancers and infectious diseases,” said David Kim, CEO of Cure Therapeutics.
Under the deal, the parties will collaborate in developing and commercializing Cure Therapeutics’ pipeline on a global basis, as well as developing, commercializing and supplying Orgenesis’ therapeutic pipeline in South Korea and Japan.
Cure Therapeutics and Orgenesis will contribute at least US$10m to the JV to cover operating costs, US$5m of which may be provided in the form of in-kind contribution.
The partnership is set to initially focus on aligning the efforts of both companies to advance proprietary Orgenesis CAR-T, TILS and DUVAC therapies into clinical trials in South Korea and Japan.
Vered Caplan, CEO of Orgenesis, acknowledged Cure Therapeutics’ expertise in those Asian markets, as well as the Korean company’s robust immunotherapy pipeline.
The future of treatment for many of the most challenging diseases in the world is said to reside in personalized cell and gene therapy (CGT). These expensive and complex therapies have proven highly effective in multiple cases, but challenges remains around producing them at scale and at a reasonable cost. Orgenesis is championing a model that aims to bring down those costs – it works with partner hospitals throughout the commercialization process.
It identifies promising new therapies and leverages its point of care (POCare) Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.
